Get above the noise
Log in for answers tailored to you — saved chats, your topics, and the full IJR suite.
Topic
Free account · your comment posts right after signup
Eli Lilly announced positive Phase 3 results for retatrutide in TRIUMPH-2 and TRIUMPH-3, showing substantial weight loss and improved metabolic and cardiovascular risk markers, with average losses ranging roughly from the high 20s to the mid-50s pounds across different doses. The company plans to submit a Biologics License Application to the FDA in early 2027 as it moves toward global regulatory submissions for obesity and related conditions.